Why the study?
Does delapril hydrochloride improve PIIIP, LVM, and cardiac function in hypertensive patients?
Does delapril hydrochloride improve PIIIP, LVM, and cardiac function in hypertensive patients?
Long-term treatment with delapril hydrochloride in hypertensive patients reduces PIIIP and LVM while improving cardiac function.
May support delapril for LV remodeling in hypertension; hypothesis-generating and requires randomized confirmation before practice change.
The long-term effect of delapril hydrochloride, a non-sulfhydryl angiotensin converting enzyme inhibitor, on serum concentrations of procollagen type III amino-terminal peptide (PIIIP) and left ventricular mass (LVM) and function were investigated in 15 hypertensive patients. Patients were treated with delapril hydrochloride 30 mg/day po for 12 months. Blood samples and an echocardiogram were obtained before treatment and after 6 and 12 months of treatment. Blood pressure, PIIIP, and LVM significantly decreased associated with an increase in left ventricular fractional shortening and mean systolic and diastolic posterior wall velocity at 6 and 12 months of treatment. Positive correlations between PIIIP and LVM (r=0.49, p<0.005) and negative correlations between PIIIP and left ventricular fractional shortening (r=-0.31, p<0.05) were found. Delapril hydrochloride reduced PIIIP and LVM and improved cardiac function in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Matoba et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: